Alphazyme Enters into Licensing Agreement with Dyadic International
May 08, 2019
Share
Dyadic International, Inc. has entered into a sub-licensing agreement with Alphazyme LLC (Alphazyme). Under the terms of the Sub-License Agreement, Dyadic has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc.
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
DYADIC INTERNATIONAL, INC. 
